Eisai Unveils Lecanemab Data Following Reports of Second Alzheimer’s Patient Death
Before the FDA’s upcoming approval decision for Eisai’s Alzheimer’s treatment, lecanemab, the company released Phase 3 study data from the confirmatory CLARITY AD trial. The release comes just days after reports of a second patient death in the trial, which Eisai addressed, saying both deaths resulted from substantial comorbidities and risk factors, not from lecanemab.
It's free! Log in now to read